治疗黑色素瘤的 T 细胞免疫疗法。

IF 2.3 4区医学 Q3 ONCOLOGY

Surgical Oncology-Oxford Pub Date : 2024-11-08 DOI:10.1016/j.suronc.2024.102160

Cristian Mantilla Rosa , Aparna Vancheswaran , Charlotte E. Ariyan

引用次数: 0

摘要

本综述探讨了黑色素瘤的T细胞免疫疗法，重点介绍免疫检查点抑制剂（抗CTLA-4、抗PD-1、抗LAG-3）、肿瘤浸润淋巴细胞（TILs）以及具有特异性受体或T细胞受体的新兴疗法，如CAR-T和TCR细胞以及RNA疫苗。我们将讨论 T 细胞免疫疗法的历史、作用机制以及改善患者预后的未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

T-cell immunotherapy for melanoma

This review explores T-cell immunotherapy for melanoma, highlighting immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-LAG-3), tumor-infiltrating lymphocytes (TILs), and emerging therapies that engineer T cells with specific receptors or T-cell receptors, such as CAR-T and TCR cells, and RNA vaccines. We discuss the history of T-cell immunotherapy, mechanisms of action, and future directions for improving patient outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Surgical Oncology-Oxford 医学-外科

CiteScore

4.50

自引率

0.00%

发文量

169

审稿时长

38 days

期刊介绍： Surgical Oncology is a peer reviewed journal publishing review articles that contribute to the advancement of knowledge in surgical oncology and related fields of interest. Articles represent a spectrum of current technology in oncology research as well as those concerning clinical trials, surgical technique, methods of investigation and patient evaluation. Surgical Oncology publishes comprehensive Reviews that examine individual topics in considerable detail, in addition to editorials and commentaries which focus on selected papers. The journal also publishes special issues which explore topics of interest to surgical oncologists in great detail - outlining recent advancements and providing readers with the most up to date information.